Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease

Journal of Obstetrics and Gynaecology

Volumn 27, Issue 1, 2007, Pages 82-83

  Tan, T L ^a   Ahmad, H ^a   Jhavar, R ^a   Patel, R ^a   Harrison, C ^a   Oteng Ntim, E ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC HYDROXIDE SUCROSE; FERROUS SULFATE; IRON; RECOMBINANT ERYTHROPOIETIN; TRANEXAMIC ACID;

ADULT; ARTICLE; CASE REPORT; CESAREAN SECTION; FEMALE; HUMAN; JEHOVAH'S WITNESS; PREGNANT WOMAN; PRIORITY JOURNAL; SICKLE CELL ANEMIA;

ADULT; ANEMIA, SICKLE CELL; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HUMANS; JEHOVAH'S WITNESSES; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC;

EID: 33847020082     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.1080/01443610601062739     Document Type: Article

References (4)

1. Breymann C, Fibach E, Visca E et al. 1999. Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. Journal of Maternal Fetal Medicine 8:1-7.
2. de Klerk G, Rosengarten PC, Vet RJ, Goudsmit R. 1981. Serum erythropoietin (EST) titers in anemia. Blood 58:1164-1170.
3. Nissenson AR. 1994. Erythropoietin overview - 1993. Blood Purification 12:6-13.
4. Smith KJ, Bleyer AJ, Little WC, Sane DC. 2003. The cardiovascular effects of erythropoietin. Cardiovascular Research 59:538-548.